Randomized Double-blind Trial to Study the Benefit of Colchicine in Patients With Acutely Decompensated Heart Failure (COLICA)

Heart failure (HF) is a chronic disease associated with multiple acute decompensations, which are the main cause of hospital admission above 65 years and two thirds of the high costs associated with the disease. Furthermore, in the patient they reflect a phase of clinical instability, with a higher risk of early readmission (20-30% at 30 days) and higher mortality (10-15% at 30 days and 30-40% at 1year).

However, the investigators do not have treatments specifically aimed at this unstable phase, known as acute or decompensated (HF). It is known that, in this acute and unstable state, there is an increase in inflammatory parameters. Indeed, our group has recently demonstrated the relevance of the interleukin-1 axis, in particular IL-1beta and sST2 concentrations identified a worse prognosis regardless of HF phenotype. Colchicine, a widely available drug, has proven to be a powerful cardiovascular anti-inflammatory, acting on inflammasome and therefore inhibiting the production of IL1-beta.The study hypothesis is that colchicine administered early during the acute phase can promote stability in terms of biomarkers of cardiac function and new decompensations. For this it is designed a randomized, double-blind clinical study with two arms (colchicine 0.5 mg vs. placebo) initiated within the first 24 hours of hospitalisation and administered for 60 days, in patients with acute decompensated HF with either reduced or preserved LV ejection fraction.

Study Overview

• Status: Completed
• Conditions: HEART FAILURE
• Intervention / Treatment: Drug: Colchicine 0.5 MG; Drug: Placebo

Detailed Description

The primary objective of the study is the reduction of NT-proBNP at two months of treatment. A secondary objective is to attain a greater clinical stability, in terms of reduction of new HF decompensations and need for diuretics, and symptoms improvement. The calculated population size is 278 patients. Follow-up visits will be carried out at discharge, 7 days, 4 weeks and 8 weeks after the hospital discharge. The potential of the study is very high given the high prevalence and clinical impact of HF hospitalizations, together with the absence of specific treatment for this phase of the disease. Therefore, in case of a positive result, this would mean a huge clinical, social and health benefits, as well as being an important therapeutic progress.

• Study Type: Interventional
• Enrollment (Actual): 279
• Phase: Phase 3

Contacts and Locations

Study Locations

• Spain
  • Murcia, Spain, 30120
    • Hospital Clínico Universitario Virgen de la Arrixaca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Unscheduled visit for symptoms and / or congestive signs of HF that require treatment with intravenous diuretics (at least 40 mg intravenous furosemide)
2. Clinical evidence, by symptoms or signs, and / or radiological of congestion.
3. NT-proBNP concentration greater than 900 pg / ml at screening visit.
4. Age over 18 years.
5. Patients who have given their informed consent in writing.

Exclusion Criteria:

1. Severe valve disease with indication for surgical repair.
2. Extracardiac disease with estimated vital prognosis of less than 1 year.
3. Inflammatory bowel disease (Crohn's disease or ulcerative colitis), diarrhea chronic or malabsorption.
4. Rheumatic inflammatory disease.
5. Serious gastrointestinal disorders
6. Stomach ulcer
7. Hematological disorders, such as blood dyscrasias
8. Previous neuromuscular disease
9. Severe renal failure (glomerular filtration rate <30 ml / kg / min / 1.73m2)
10. History of cirrhosis, chronic active hepatitis or severe liver disease, defined by GOT (AST) or GPT (ALT) values that exceed 3 x upper limit of normality
11. Patient who is taking colchicine for other indications (mainly chronic prescriptions for familial Mediterranean fever or gout). No washout period will be required for patients who have been treated with colchicine and have stopped treatment prior to randomization.
12. Patient with a history of allergic reactions or significant sensitivity to colchicine.
13. Chronic treatment with immunosuppressants, corticosteroids, interleukin-1 antagonists in the 6 months prior to inclusion.
14. Pregnant or lactating women, where pregnancy is defined as the state of a woman after conception and until the end of gestation, confirmed by a positive test result for human chorionic gonadotropin (hCG), or planned become pregnant or plan to breastfeed during study treatment or within 30 days of the end of study drug treatment.
15. Woman of childbearing potential who is unwilling to inform her partner of her participation in this clinical study or to use 2 effective contraceptive methods that are acceptable or to practice strict sexual abstinence (the investigator must assess the reliability of sexual abstinence and make it the preferred and usual lifestyle of the subject) during treatment with study drug (colchicine or placebo) and for an additional 30 days after the last dose of study drug.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Placebo 1c/24h Treatment 8 weeks
Experimental: Experimental; Colchicine 0.5 mg	Drug: Colchicine 0.5 MG; Colchicine 0.5 mg/24h Treatment 8 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Decreased NT-proBNP levels	Decreased (N-terminal prohormone of brain natriuretic peptide) levels	Up to 8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improvement of clinical stability	dose of intravenous diuretics	Up to 8 weeks
Improvement of clinical stability	NYHA (New York Heart Association) Scale . Level 1 to 4. Level 1 is the one with the least limitation or symptoms.	Up to 8 weeks
Improvement of clinical stability	EVA scale . Level 1 to 10 . Level 1 is the one with the least pain, limitation or symptoms.	Up to 8 weeks
Improvement of clinical stability	LIKERT scale. Level 1 to 5 . Level 1 expresses the patient's agreement with a specific aspect.	Up to 8 weeks
Improvement of clinical stability	Number of Acute Decompensation Episodes	Up to 8 weeks
Improvement of clinical stability	Number of Congestion Episodes	Up to 8 weeks
Improvement of clinical stability	biomarkers (hsTnT, IL-1 beta, IL-6, sST2 y CA125.)	Up to 8 weeks
Mortality rate reduction		Up to 8 weeks
Total days of hospitalization		Up to 8 weeks

Collaborators and Investigators

• Sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
• Investigators: Principal Investigator: Domingo Pascual Figal, MD, Hospital Clínico Universitario Virgen de la Arrixaca

Study record dates

Study Major Dates

• Study Start (Actual): February 8, 2021
• Primary Completion (Actual): May 17, 2024
• Study Completion (Actual): May 17, 2024

Study Registration Dates

• First Submitted: January 11, 2021
• First Submitted That Met QC Criteria: January 11, 2021
• First Posted (Actual): January 12, 2021

Study Record Updates

• Last Update Posted (Actual): May 22, 2024
• Last Update Submitted That Met QC Criteria: May 21, 2024
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure; Molecular Mechanisms of Pharmacological Action; Antirheumatic Agents; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Gout Suppressants; Colchicine
• Other Study ID Numbers: IMIB-CO-2020-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No